

Dynavax Technologies

08:33 22 Oct 2018

Dynavax Technologies shares climb after drug test to treat melanoma shows positive response rate

Dynavax Technologies Corporation (NASDAQ:DVAX) shares rose on Monday after reporting a 70% overall response rate when using their drug in combination with another treatment for advanced melanoma, the most dangerous form of skin cancer.

The combination of Dynavax's SD-101 with Keytruda, a drug developed by Merck & Co Inc (NYSE:MRK) was tolerated well by patients taking part in the study, the company said in a presentation at a medicaql conference in Munich, Germany.

"These results are encouraging because the overall response rate in the 2 mg group has remained consistent with the data presented at the 2018 American Society for Clinical Oncology annual meeting, even though the number of patients increased by more than 50%," said Rob Janssen, the chief medical officer.

"In addition, median progression-free survival has not yet been reached, but statistically is expected to be at least 15.2 months, providing further validation of the potential benefit of the combination therapy," he said.

Shares of Dynavax gained 19.8% to \$13.05, having closed on Friday down 4.22% at \$10.89.

READ: Dynavax shares set to rise on 'encouraging' results of cancer drug SD-101, the company's lead clinical candidate, is a second-generation, which is being evaluated by the company in several clinical studies to assess its safety and activity, including a Phase 2 study in combination with Keytruda, a therapy in patients with advanced melanoma and in patients with head and neck squamous cell cancer.

In the clinical collaboration with Merck. Dynavax maintains all commercial rights to SD-101.

Dynavax is a biopharmaceutical company focused on leveraging the power of the body's immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics.

The company is based in Berkeley, California.

Reporting by Rene Pastor, contactable on rene.pastor@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 6.92

Market Cap: \$580.35 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: DVAX

Listing: NASDAQ

52 week High Low
12.41 2.595

Sector: Medical technology & services

Website:

Company Synopsis:

Dynavax Technologies Corporation (Dynavax) is a biopharmaceutical company that discovers and develops products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases.

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.